These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 24584911)
1. Tumor lysis syndrome in a chronic lymphocytic leukemia patient with pleural effusion after oral fludarabine and cyclophosphamide therapy. Nakazawa H; Nishina S; Mimura Y; Kawakami T; Senoo Y; Sakai K; Nakazawa K; Kitano K Int J Hematol; 2014 Jun; 99(6):782-5. PubMed ID: 24584911 [TBL] [Abstract][Full Text] [Related]
2. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase. Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266 [TBL] [Abstract][Full Text] [Related]
3. Acute tumour lysis syndrome after oral fludarabine in a patient with chronic lymphocytic leukaemia. Ramachandran A; Majumdar G Hematol J; 2004; 5(6):528-9. PubMed ID: 15570297 [TBL] [Abstract][Full Text] [Related]
4. Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase. Calvo-Villas JM; Urcuyo BM; Umpierrez AM; Sicilia F Onkologie; 2008 Apr; 31(4):197-9. PubMed ID: 18418022 [TBL] [Abstract][Full Text] [Related]
5. Hemorrhagic pleural effusion as a complication of chronic lymphocytic leukemia. Zeidman A; Yarmolovsky A; Djaldetti M; Mittelman M Haematologia (Budap); 1995; 26(3):173-5. PubMed ID: 7797147 [TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial. Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003 [TBL] [Abstract][Full Text] [Related]
7. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. Robak T; Lech-Maranda E; Robak P Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624 [TBL] [Abstract][Full Text] [Related]
8. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy. Weiss MA; Glenn M; Maslak P; Rahman Z; Noy A; Zelenetz A; Scheinberg DA; Golde DW Leukemia; 2000 Sep; 14(9):1577-82. PubMed ID: 10995003 [TBL] [Abstract][Full Text] [Related]
9. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy. Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133 [TBL] [Abstract][Full Text] [Related]
10. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia. Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952 [TBL] [Abstract][Full Text] [Related]
11. Acute tumor lysis syndrome during oral fludarabine treatment for CLL--a rare event that might be observed more frequently in the future. Rioufol C; Coiffier B Onkologie; 2008 Apr; 31(4):157-8. PubMed ID: 18418014 [No Abstract] [Full Text] [Related]
12. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844 [TBL] [Abstract][Full Text] [Related]
13. Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature. Hussain K; Mazza JJ; Clouse LH Am J Hematol; 2003 Mar; 72(3):212-5. PubMed ID: 12605395 [TBL] [Abstract][Full Text] [Related]
14. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance. García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA; Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600 [TBL] [Abstract][Full Text] [Related]
15. Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. Cheson BD; Frame JN; Vena D; Quashu N; Sorensen JM J Clin Oncol; 1998 Jul; 16(7):2313-20. PubMed ID: 9667245 [TBL] [Abstract][Full Text] [Related]
16. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Johnson S; Smith AG; Löffler H; Osby E; Juliusson G; Emmerich B; Wyld PJ; Hiddemann W Lancet; 1996 May; 347(9013):1432-8. PubMed ID: 8676625 [TBL] [Abstract][Full Text] [Related]
17. Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis. Nunes AA; da Silva AS; Souza KM; Koury Cde N; de Mello LM Crit Rev Oncol Hematol; 2015 Jun; 94(3):261-9. PubMed ID: 25797826 [TBL] [Abstract][Full Text] [Related]
18. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Keating MJ; O'Brien S; Albitar M; Lerner S; Plunkett W; Giles F; Andreeff M; Cortes J; Faderl S; Thomas D; Koller C; Wierda W; Detry MA; Lynn A; Kantarjian H J Clin Oncol; 2005 Jun; 23(18):4079-88. PubMed ID: 15767648 [TBL] [Abstract][Full Text] [Related]
19. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Eichhorst BF; Busch R; Hopfinger G; Pasold R; Hensel M; Steinbrecher C; Siehl S; Jäger U; Bergmann M; Stilgenbauer S; Schweighofer C; Wendtner CM; Döhner H; Brittinger G; Emmerich B; Hallek M; Blood; 2006 Feb; 107(3):885-91. PubMed ID: 16219797 [TBL] [Abstract][Full Text] [Related]
20. Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents. Cheson BD; Heitner Enschede S; Cerri E; Desai M; Potluri J; Lamanna N; Tam C Oncologist; 2017 Nov; 22(11):1283-1291. PubMed ID: 28851760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]